清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Abstract 1546: ADCC enhanced anti-CD25 mAb (TST010) demonstrated antitumor activity via depleting Treg cells and increasing CD8+T/Treg ratio in preclinical tumor models

白细胞介素2受体 抗体依赖性细胞介导的细胞毒性 FOXP3型 癌症研究 单克隆抗体 细胞毒性T细胞 肿瘤微环境 生物 效应器 T细胞 免疫系统 免疫学 细胞生物学 抗体 体外 生物化学
作者
Di Sun,Huanhuan Guo,Hongjun Li,Xinlai Yao,Yiqing Xu,Shenjie Zhang,Shijie Zhou,Xiaoli Zi,Lisa Zheng,Yi Gu,Xueming Qian
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:83 (7_Supplement): 1546-1546
标识
DOI:10.1158/1538-7445.am2023-1546
摘要

Abstract Regulatory T (Treg) cells are a distinctive lineage of CD4+ T cells as characterized by expression of FoxP3 and CD25 markers. Treg cells are involved in tumor development and progression by inhibiting antitumor immunity. Accumulation of Treg cells in the tumor microenvironment (TME) is often associated with an adverse prognosis in multiple cancers and also has implication for predicting response to immunotherapy. Treg cell depletion strategy has been explored in preclinical and clinical settings to induce effective antitumor immune responses in TME. CD25, a high-affinity binding subunit alpha of the IL-2 receptor, is constitutively and highly expressed on Treg cells but also transiently upregulated on effector T cells. The high level of CD25 expression on Treg cells could deprive of IL-2 for effector T cells and inhibit their proliferation. Thus, an effective approach to selectively suppress Treg cell function is to deplete Treg cells while avoid blocking IL-2 binding to CD25 for allowing T effect cell proliferation and activation. Using our immune tolerance breaking antibody platform, we generated a humanized IgG1 subtype anti-CD25 monoclonal antibody (TST010). TST010 bound to human CD25 with high affinity and selectivity but did not block IL-2 binding to CD25. No blocking activity to IL-2 signaling on human PBMC was further confirmed by the phosphorylation of Stat5 using FACS analysis. By reducing fucosylation during cell culture process, TST010 mAb gained the enhanced ADCC activity. In an ADCC reporter assay, TST010 showed its sub-nanomolar ADCC activity against CD25-overexpression SU-DHL-1 cell line and human induced Treg cells, but much less to human activated CD8+ T effect cells due to lower CD25 expression. Similarly, in a NK cytotoxicity assay, TST010 selectively killed human induced Treg cells in contrast to activated CD8+ T cells. In vivo antitumor activity of TST010 was evaluated in the syngeneic mouse tumor models. The mouse colon cancer MC38 model was developed on the human CD25 knock-in mice. In the MC38 tumor model, TST010 markedly reduced the Treg (FoxP3+CD4+) population in both peripheral blood and TME. Importantly, the CD8+T/Treg ratio in tumor was increased starting at 2 weeks post TST010 treatment, and it resulted in a significant single agent tumor growth inhibition at a 10 mg/kg dose. Furthermore, in the LLC tumor model which does not respond well to checkpoint inhibitors, the anti-CD25 mAb showed a good combination effect with a PD-L1 inhibitor. In summary, we have discovered a novel therapeutic anti-CD25 mAb that can deplete Treg cells without blocking IL-2 signaling. As demonstrated in our preclinical tumor models, it has a good potential to induce effective antitumor immune responses in TME and tumor growth inhibition especially in combination with PD-1/PD-L1 treatment. Citation Format: Di Sun, Huanhuan Guo, Hongjun Li, Xinlai Yao, Yiqing Xu, Shenjie Zhang, Shijie Zhou, Xiaoli Zi, Lisa Zheng, Yi Gu, Xueming Qian. ADCC enhanced anti-CD25 mAb (TST010) demonstrated antitumor activity via depleting Treg cells and increasing CD8+T/Treg ratio in preclinical tumor models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1546.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
落后的山槐完成签到,获得积分10
11秒前
36秒前
LY发布了新的文献求助10
43秒前
活力尔柳完成签到 ,获得积分10
43秒前
lilylwy完成签到 ,获得积分0
43秒前
朝朝的应助被萧雨墨采纳,获得10
44秒前
单纯的天抒完成签到,获得积分10
44秒前
Maestro_S的应助被科研通管家采纳,获得10
1分钟前
1分钟前
LY完成签到,获得积分10
1分钟前
彩色听筠完成签到,获得积分10
1分钟前
文静的丹彤完成签到,获得积分10
1分钟前
勤劳觅山完成签到,获得积分10
1分钟前
专注寒蕾完成签到,获得积分10
2分钟前
分手吧亚索完成签到 ,获得积分10
2分钟前
无极微光的应助被科研通管家采纳,获得20
3分钟前
3分钟前
3分钟前
3分钟前
urah完成签到,获得积分10
3分钟前
万能图书馆的应助被urah采纳,获得10
3分钟前
yuanmeng434完成签到 ,获得积分10
3分钟前
lily完成签到 ,获得积分10
3分钟前
神勇寄风完成签到,获得积分10
3分钟前
李祺完成签到 ,获得积分10
3分钟前
落寞的姿完成签到,获得积分10
4分钟前
火柴盒完成签到,获得积分10
4分钟前
漂亮的乐曲完成签到,获得积分10
4分钟前
Maestro_S的应助被科研通管家采纳,获得10
5分钟前
5分钟前
5分钟前
5分钟前
urah发布了新的文献求助10
5分钟前
愤怒的微笑完成签到,获得积分10
5分钟前
宣灵薇完成签到 ,获得积分0
5分钟前
浮华乱世完成签到 ,获得积分10
5分钟前
风趣的莫英完成签到,获得积分10
5分钟前
沉默怡完成签到,获得积分10
6分钟前
Bonnie完成签到 ,获得积分10
6分钟前
liunahan完成签到 ,获得积分10
6分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190226
求助须知:如何正确求助?哪些是违规求助? 9577355
关于积分的说明 21852358
捐赠科研通 7788741
什么是DOI,文献DOI怎么找? 3436310
关于科研通互助平台的介绍 2560106
邀请新用户注册赠送积分活动 2482902